News

Cookie Notification

We use cookies to collect information about how our website is used and to improve the visitor experience. You can change your browser's cookie settings at any time. Please review our privacy policy for more information. OK

Media Contact

Stephen Schultz
VP Investor Relations (U.S.)
T: 917-280-2424 / 401 500 6570
sschultz@gwpharm.com
 

Recent Press Releases

Dec 22, 2014
London, UK, 22 December 2014: GW Pharmaceuticals plc (NASDAQ: GWPH, AIM: GWP, GW, the Company or the Group), a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from
Dec 02, 2014
-Conference Call Today at 8:00 a.m. ET, 1:00 p.m. GMT-
Nov 24, 2014
London, UK, 24 November 2014: GW Pharmaceuticals plc (Nasdaq: GWPH, AIM: GWP, “GW” or “the Company”), a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its pr
Nov 17, 2014
London, UK, 17 November 2014: GW Pharmaceuticals plc (Nasdaq: GWPH, AIM: GWP, “GW,” “the Company” or “the Group”), a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutic
Oct 30, 2014
London, UK; 30 Oct 2014: GW Pharmaceuticals plc (Nasdaq: GWPH, AIM: GWP, “GW,” “the Company” or “the Group”), a biopharmaceutical company focused on discovering, developing, and commercializing novel therapeutics fr
Oct 22, 2014
London, UK; 22 October 2014: GW Pharmaceuticals plc (Nasdaq: GWPH, AIM: GWP, “GW,” “the Company” or “the Group”), a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics
Oct 14, 2014
- Trial data show promising signals of efficacy in patients who completed course of treatment -
Oct 14, 2014
- Physician reports show signals of efficacy and safety consistent with previously disclosed data, as well as maintenance of clinical effect beyond 12 weeks and high retention rate -
Oct 06, 2014
Lorem ipsum dolor sit met, consectetuer aqipiscing elit. Aeneas kommod ligula eget dolor. Aegean massa. Cum socks natoque penatibus et manies dis parturient montes, nascetur ridiculous mus. Donc quai felis, ultricies nec, pellentesque eu, pretium quis, sem. Nulla consequent massa quis enim.
Sep 29, 2014
London, UK, 29 September 2014: GW Pharmaceuticals plc (Nasdaq: GWPH, AIM: GWP, “GW,” “the Company” or “the Group”), a biopharmaceutical company focused on discovering, developing and commercializing novel therapeuti

Pages